CoChat

The structural basis for HIV-1 Vif antagonism of human APOBEC3G

Open access
Li, Yen-Li, Langley, Caroline A., Azumaya, Caleigh M., Echeverria, Ignacia, Chesarino, Nicholas M., Emerman, Michael, Cheng, Yifan, Gross, John D. · 2023 · Nature
Cited by 71

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

The APOBEC3 (A3) proteins are host antiviral cellular proteins that hypermutate the viral genome of diverse viral families. In retroviruses, this process requires A3 packaging into viral particles 1–4. The lentiviruses encode a protein, Vif, that antagonizes A3 family members by targeting them for degradation. Diversification of A3 allows host escape from Vif whereas adaptations in Vif enable cross-species transmission of primate lentiviruses. How this ‘molecular arms race’ plays out at the structural level is unknown. Here, we report the cryogenic electron microscopy structure of human APOBEC3G (A3G) bound to HIV-1 Vif, and the hijacked cellular proteins that promote ubiquitin-mediated proteolysis. A small surface explains the molecular arms race, including a cross-species transmission event that led to the birth of HIV-1. Unexpectedly, we find that RNA is a molecular glue for the Vif–A3G interaction, enabling Vif to repress A3G by ubiquitin-dependent and -independent mechanisms. Our results suggest a model in which Vif antagonizes A3G by intercepting it in its most dangerous form for the virus—when bound to RNA and on the pathway to packaging—to prevent viral restriction. By engaging essential surfaces required for restriction, Vif exploits a vulnerability in A3G, suggesting a general mechanism by which RNA binding helps to position key residues necessary for viral antagonism of a host antiviral gene.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-05779-1

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 78

  1. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002). · DOI · Paper page
  2. Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803–809 (2003). · DOI · Paper page
  3. Pollpeter, D. et al. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. Nat. Microbiol. 3, 220–233 (2018). · DOI · Paper page
  4. Delviks-Frankenberry, K. A., Desimmie, B. A. & Pathak, V. K. Structural insights into APOBEC3-mediated lentiviral restriction. Viruses 12, 587 (2020). · DOI
  5. Uriu, K., Kosugi, Y., Ito, J. & Sato, K. The battle between retroviruses and APOBEC3 genes: its past and present. Viruses 13, 124 (2021). · DOI
  6. Cheng, A. Z. et al. APOBECs and herpesviruses. Viruses 13, 390 (2021). · DOI
  7. Harris, R. S. & Dudley, J. P. APOBECs and virus restriction. Virology 479–480, 131–145 (2015). · DOI · Paper page
  8. Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F. & Malim, M. H. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5, e1000330 (2009). · DOI · Paper page
  9. Huthoff, H. & Malim, M. H. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81, 3807–3815 (2007). · DOI · Paper page
  10. Stopak, K., de Noronha, C., Yonemoto, W. & Greene, W. C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591–601 (2003). · DOI · Paper page
  11. Anderson, B. D. & Harris, R. S. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta/RUNX axis. Sci. Adv. 1, e1500296 (2015). · DOI
  12. Binning, J. M. et al. Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors. PLoS Pathog. 14, e1006830 (2018). · DOI
  13. Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056–1060 (2003). · DOI · Paper page
  14. Khan, M. A. et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 75, 7252–7265 (2001). · DOI
  15. Compton, A. A., Hirsch, V. M. & Emerman, M. The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe 11, 91–98 (2012). · DOI
  16. Etienne, L., Hahn, B. H., Sharp, P. M., Matsen, F. A. & Emerman, M. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe 14, 85–92 (2013). · DOI
  17. Zhang, W., Du, J., Evans, S. L., Yu, Y. & Yu, X. F. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376–379 (2012). · DOI · Paper page
  18. Kouno, T. et al. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat. Struct. Mol. Biol. 22, 485–491 (2015). · DOI · Paper page
  19. Maiti, A. et al. Crystal structure of a soluble APOBEC3G variant suggests ssDNA to bind in a channel that extends between the two domains. J. Mol. Biol. 432, 6042–6060 (2020). · DOI
  20. Yang, H. et al. Understanding the structural basis of HIV-1 restriction by the full length double-domain APOBEC3G. Nat. Commun. 11, 632 (2020). · DOI
  21. Hu, Y. et al. Structural basis of antagonism of human APOBEC3F by HIV-1 Vif. Nat. Struct. Mol. Biol. 26, 1176–1183 (2019). · DOI
  22. Siu, K. K., Sultana, A., Azimi, F. C. & Lee, J. E. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 4, 2593 (2013). · DOI · Paper page
  23. Ball, K. A. et al. Conformational dynamics of the HIV-Vif protein complex. Biophys. J. 116, 1432–1445 (2019). · DOI
  24. Compton, A. A., Malik, H. S. & Emerman, M. Host gene evolution traces the evolutionary history of ancient primate lentiviruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120496 (2013). · DOI
  25. Zhang, L. et al. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370, 113–121 (2008). · doi:10.1016/j.virol.2007.08.027
  26. Conticello, S. G., Harris, R. S. & Neuberger, M. S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009–2013 (2003). · DOI · Paper page
  27. Bulliard, Y. et al. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83, 12611–12621 (2009). · DOI
  28. Russell, R. A. & Pathak, V. K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201–8210 (2007). · DOI · Paper page
  29. Gallois-Montbrun, S. et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81, 2165–2178 (2007). · DOI · Paper page
  30. Stenglein, M. D., Matsuo, H. & Harris, R. S. Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 82, 9591–9599 (2008). · DOI
  31. Kozak, S. L., Marin, M., Rose, K. M., Bystrom, C. & Kabat, D. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281, 29105–29119 (2006). · DOI · Paper page
  32. Yamashita, T., Kamada, K., Hatcho, K., Adachi, A. & Nomaguchi, M. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 10, 1142–1149 (2008). · DOI
  33. He, Z., Zhang, W., Chen, G., Xu, R. & Yu, X.-F. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381, 1000–1011 (2008). · DOI
  34. Russell, R. A., Smith, J., Barr, R., Bhattacharyya, D. & Pathak, V. K. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83, 1992–2003 (2009). · DOI
  35. Chen, G., He, Z., Wang, T., Xu, R. & Yu, X.-F. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83, 8674–8682 (2009). · DOI
  36. Chaipan, C., Smith, J. L., Hu, W. S. & Pathak, V. K. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 87, 444–453 (2013). · DOI · Paper page
  37. Letko, M. et al. Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G. J. Virol. 87, 11861–11871 (2013). · DOI
  38. York, A., Kutluay, S. B., Errando, M. & Bieniasz, P. D. The RNA binding specificity of human APOBEC3 proteins resembles that of HIV-1 nucleocapsid. PLoS Pathog. 12, e1005833 (2016). · DOI
  39. Gaba, A., Flath, B. & Chelico, L. Examination of the APOBEC3 barrier to cross species transmission of primate lentiviruses. Viruses 13, 1084 (2021). · DOI
  40. Letko, M., Booiman, T., Kootstra, N., Simon, V. & Ooms, M. Identification of the HIV-1 Vif and human APOBEC3G protein interface. Cell Rep. 13, 1789–1799 (2015). · DOI
  41. Binning, J. M., Chesarino, N. M., Emerman, M. & Gross, J. D. Structural basis for a species-specific determinant of an SIV Vif protein toward hominid APOBEC3G antagonism. Cell Host Microbe 26, 739–747 (2019). · DOI
  42. Schröfelbauer, B., Chen, D. & Landau, N. R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl Acad. Sci. USA 101, 3927–3932 (2004). · DOI · Paper page
  43. Huttenhain, R. et al. ARIH2 is a Vif-dependent regulator of CUL5-mediated APOBEC3G degradation in HIV infection. Cell Host Microbe 26, 86–99 (2019). · DOI · Paper page
  44. Iwatani, Y. et al. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl Acad. Sci. USA 106, 19539–19544 (2009). · DOI
  45. Soros, V. B., Yonemoto, W. & Greene, W. C. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3, e15 (2007). · DOI
  46. Goila-Gaur, R., Khan, M. A., Miyagi, E. & Strebel, K. Differential sensitivity of “old” versus “new” APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol. 83, 1156–1160 (2009). · DOI
  47. Gradia, S. D. et al. MacroBac: new technologies for robust and efficient large-scale production of recombinant multiprotein complexes. Methods Enzymol. 592, 1–26 (2017). · DOI · Paper page
  48. Mastronarde, D. N. SerialEM: a program for automated tilt series acquisition on Tecnai microscopes using prediction of specimen position. Microsc. Microanal. 9, 1182–1183 (2003). · DOI · Paper page
  49. de la Rosa-Trevin, J. M. et al. Scipion: a software framework toward integration, reproducibility and validation in 3D electron microscopy. J. Struct. Biol. 195, 93–99 (2016). · DOI · Paper page
  50. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017). · DOI · Paper page
  51. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017). · DOI · Paper page
  52. Bai, X. C., Rajendra, E., Yang, G., Shi, Y. & Scheres, S. H. Sampling the conformational space of the catalytic subunit of human gamma-secretase. eLife 4, e11182 (2015). · DOI · Paper page
  53. Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157, 281–287 (2007). · DOI · Paper page
  54. Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012). · DOI · Paper page
  55. Punjani, A. & Fleet, D. J. 3D variability analysis: resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. J. Struct. Biol. 213, 107702 (2021). · DOI · Paper page
  56. Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021). · DOI · Paper page
  57. Terwilliger, T. C., Ludtke, S. J., Read, R. J., Adams, P. D. & Afonine, P. V. Improvement of cryo-EM maps by density modification. Nat. Methods 17, 923–927 (2020). · DOI · Paper page
  58. Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. Quantifying the local resolution of cryo-EM density maps. Nat. Methods 11, 63–65 (2014). · DOI · Paper page
  59. Tan, Y. Z. et al. Addressing preferred specimen orientation in single-particle cryo-EM through tilting. Nat. Methods 14, 793–796 (2017). · DOI · Paper page
  60. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993). · DOI · Paper page
  61. Webb, B. & Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinformatics 54, 5.6.1–5.6.37 (2016). · DOI · Paper page
  62. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004). · DOI · Paper page
  63. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010). · DOI · Paper page
  64. Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D Struct. Biol. 74, 519–530 (2018). · DOI · Paper page
  65. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010). · DOI · Paper page
  66. Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D Struct. Biol. 74, 531–544 (2018). · DOI · Paper page
  67. Mostosi, P., Schindelin, H., Kollmannsberger, P. & Thorn, A. Haruspex: a neural network for the automatic identification of oligonucleotides and protein secondary structure in cryo-electron microscopy maps. Angew. Chem. Int. Ed. Engl. 59, 14788–14795 (2020). · DOI · Paper page
  68. Chou, F. C., Sripakdeevong, P., Dibrov, S. M., Hermann, T. & Das, R. Correcting pervasive errors in RNA crystallography through enumerative structure prediction. Nat. Methods 10, 74–76 (2013). · DOI · Paper page
  69. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010). · DOI · Paper page
  70. Afonine, P. V. et al. New tools for the analysis and validation of cryo-EM maps and atomic models. Acta Crystallogr. D Struct. Biol. 74, 814–840 (2018). · DOI · Paper page
  71. Pintilie, G. et al. Measurement of atom resolvability in cryo-EM maps with Q-scores. Nat. Methods 17, 328–334 (2020). · DOI · Paper page
  72. Young, J., Garikipati, N. & Durrant, J. D. BINANA 2: characterizing receptor/ligand interactions in Python and JavaScript. J. Chem. Inf. Model. 62, 753–760 (2022). · DOI
  73. Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F. & Schroeder, M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res. 43, W443–W447 (2015). · DOI · Paper page
  74. Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786 (2011). · DOI · Paper page
  75. Shen, M. Y. & Sali, A. Statistical potential for assessment and prediction of protein structures. Protein Sci. 15, 2507–2524 (2006). · DOI · Paper page
  76. Kostrhon, S. et al. CUL5-ARIH2 E3-E3 ubiquitin ligase structure reveals cullin-specific NEDD8 activation. Nat. Chem. Biol. 17, 1075–1083 (2021). · DOI · Paper page
  77. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004). · DOI · Paper page
  78. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320–W324 (2014). · DOI · Paper page

Cited by

See all 71

Metadata

Authors
Li, Y.-L., Langley, C. A., Azumaya, C. M., Echeverria, I., Chesarino, N. M., Emerman, M., Cheng, Y., & Gross, J. D.
Venue
Nature
Published
2023-02-08
Volume
615
Issue
7953
Pages
728-733
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4319656581
Cited by
71
References
15
FWCI
8.44
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The structural basis for HIV-1 Vif antagonism of human APOBEC3G. https://app.cochat.ai/papers/10.1038/s41586-023-05779-1
The paper
Li, Y.-L., Langley, C. A., Azumaya, C. M., Echeverria, I., Chesarino, N. M., Emerman, M., Cheng, Y., & Gross, J. D. (2023). The structural basis for HIV-1 Vif antagonism of human APOBEC3G. Nature. https://doi.org/10.1038/s41586-023-05779-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.